T3 Labs, the industry leading preclinical CRO, a wholly owned subsidiary of GCMI has been acquired by Veranex, a multinational preclinical contract research organization and medtech solution provider, effective November 30, 2023.
GCMI will remain a non-profit 501(c)(3) organization and an affiliate of the Georgia Institute of Technology. GCMI will continue to provide medtech product design, development and engineering services to the global medtech ecosystem.
Sherry Farrugia, who has led GCMI and T3 Labs for the past three years as Chief Executive Officer, has taken a position with Veranex. The entirety of the GCMI team thanks Sherry for her years of exceptional leadership and service to GCMI and to the stakeholders and patients that benefit from our collective efforts.
Saylan Lukas
Previously Director of R&D Engineering, Saylan Lukas has been appointed Interim Executive Director of GCMI and will lead the organization moving forward. Evan Goldberg, PhD, will remain GCMI Director of Scientific Affairs.
As we have for the past decade, GCMI will continue to work with academic investigators, entrepreneurs, and medical device companies to design, develop, and commercialize innovative medical products that improve quality-based outcomes and delivery of healthcare to patients.
This change does not impact any ongoing projects or contracts currently in place. We will continue to interact with and serve our academic and industry partners as we have in the past. There will be no immediate changes to the location of equipment and facilities.
For clients whose projects currently or potentially span both product development and preclinical service lines, GCMI will continue to collaborate with Veranex to execute preclinical studies. If you have a separate service agreement with T3 Labs you should expect to receive communication from Veranex.
We encourage those with questions about the transition to reach out to us directly. Email info@devices.net for the time being. You can now find our team online at https://gcmiatl.org.